BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Argyle Therapeutics, Inc Out-Licenses SIG990 to Brickell Biotech for Topical Treatment of Rosacea


4/17/2012 10:09:11 AM

PRINCETON, N.J., April 17, 2012 /PRNewswire/ -- Argyle Therapeutics, Inc., ("Argyle"), a biopharmaceutical company focused on the discovery and development of innovative products in the field of dermatology has entered into a partnership with Brickell Biotech ("BBI") to develop a topical treatment for rosacea. The out-licensing deal is for a novel anti-inflammatory compound, SIG990, which has the potential to reduce erythema and decrease the pastules and pustules associated with the disease. The agreement provides Argyle milestone payments and royalties with Brickell receiving the exclusive rights for SIG990 in the field of dermatology.

Several topical rosacea treatments are currently on the market or in development. However, these drugs either have safety concerns or only treat the erythema or inflammatory lesions associated with rosacea, but not both. A safe topical treatment that addresses both would be a significant and potentially better therapeutic option for rosacea patients.

Maxwell Stock, CEO of Argyle Therapeutics, Inc., commented, "We are excited to be working in collaboration with Brickell's team of experienced drug developers and look forward to advancing SIG990 into the clinic. Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing effective drugs."

Andrew Sklawer, Vice President, Operations at Brickell Biotech, Inc. also stated: "SIG990 is a valuable addition to our pipeline, as it fits with our development strategy of focusing on novel therapeutics for the treatment of skin and ocular surface diseases. We are very excited about this partnership and are looking forward to progressing the development of SIG990 as a novel therapy for the treatment of rosacea."

About Argyle Therapeutics

Argyle was formed and founded in December 2010 and is a spin-out of Signum Biosciences. Argyle is a dermatology focused company developing novel cosmetic ingredients and drug compounds to address several skin conditions and major medical needs. Small molecules are developed from our proprietary Isoprenylcysteine (IPC) technology platform. Argyle also provides dermatology testing and custom assay development services.

About Brickell Biotech

BBI is a development-stage biopharmaceutical company focused on developing a R&D pipeline with innovative molecules that have potential to meet high unmet medical needs in the dermatology and ophthalmology fields. Working in collaboration with external research organizations, BBI will efficiently move forward with the development of these compounds through the various phases of clinical testing, regulatory filings and commercialization.

SOURCE Argyle Therapeutics, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->